The impact of bone marrow-derived mesenchymal stem cells on neovascularisation in rats with brain injury

Hu, Wei; Jiang, Jian; Feng, Yu; Li, Jun

doi:10.5114/fn.2018.76615

Cited by 13 publications

(15 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In treating TBI, re-establishing blood flow to the injured area is critical for cellular growth and recovery. Endothelial progenitor cells (EPCs) promote angiogenesis through tissue repair and can be mobilized under various stimulating factors, including vascular endothelial growth factor (VEGF) [34]. However, VEGF and other vascular growth factor levels are reduced following TBI [35].…”

Section: Mesenchymal Stem Cell Therapies For Tbimentioning

confidence: 99%

“…A multitude of studies have demonstrated that BMSCs have an angiogenic effect in promoting neurologic recovery in TBI animal models. Hu et al found that BMSC transplantation increased the number of EPCs in the peripheral blood of rats with TBI 24 hours after injury, which correlated with improved modified neurological severity scores (mNSS) compared to controls [34]. This effect was also investigated by Guo et al, who demonstrated that BMSCs administered intravenously post-TBI upregulated VEGF and angiogenin-1 levels in a rat controlled cortical impact (CCI) TBI model.…”

Section: Mesenchymal Stem Cell Therapies For Tbimentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Cell-Based Therapies for Traumatic Brain Injuries

et al. 2019

View full text Add to dashboard Cite

Traumatic brain injuries (TBIs) are a leading cause of death and disability. Additionally, growing evidence suggests a link between TBI-induced neuroinflammation and neurodegenerative disorders. Treatments for TBI patients are limited, largely focused on rehabilitation therapy, and ultimately, fail to provide long-term neuroprotective or neurorestorative benefits. Because of the prevalence of TBI and lack of viable treatments, new therapies are needed which can promote neurological recovery. Cell-based treatments are a promising avenue because of their potential to provide multiple therapeutic benefits. Cell-based therapies can promote neuroprotection via modulation of inflammation and promote neurorestoration via induction of angiogenesis and neurogenesis. Neural stem/progenitor cell transplantations have been investigated in preclinical TBI models for their ability to directly contribute to neuroregeneration, form neural-like cells, and improve recovery. Mesenchymal stem cells (MSCs) have been investigated in clinical trials through multiple different routes of administration. Intravenous administration of MSCs appears most promising, demonstrating a robust safety profile, correlation with neurological improvements, and reductions in systemic inflammation following TBI. While still preliminary, evidence suggests cell-based therapies may become a viable treatment for TBI based on their ability to promote neuroregeneration and reduce inflammation.

show abstract

Section: Mesenchymal Stem Cell Therapies For Tbimentioning

confidence: 99%

Section: Mesenchymal Stem Cell Therapies For Tbimentioning

confidence: 99%

Efficacy of Cell-Based Therapies for Traumatic Brain Injuries

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Besides, inflammation and degeneration process in neurons lasts for years after TBI, causing chronic symptoms in TBI patients [13]. There is plenty of treatments for TBI nowadays, including traditional medicine treatment, transplanting neural stem cells (NSCs) and bone marrow-derived mesenchymal stem cells [14]. Among them, tetrahydroxystilbene glucoside (TSG) is extracted from traditional Chinese medicine, and has anti-atherosclerosis, hepatoprotective and hypolipidemic effects.…”

Section: Discussionmentioning

confidence: 99%

PARP1 might enhance the therapeutic effect of tetrahydroxystilbene glucoside in traumatic brain injury via inhibition of Ras/JNK signalling pathway

Cao

Chen

Wang

et al. 2020

View full text Add to dashboard Cite

Trauma is the main cause of death for people aged 1-45, and among them, traumatic brain injury (TBI) is the major condition, which causes over 50,000 deaths each year and costs over 80 billion per year. Tetrahydroxystilbene glucoside (TSG) is the active ingredient of polygonum multiflorum, a traditional Chinese herbal medicine, which presented multiple pharmacological effects, including antioxidative, anti-inflammatory, reducing blood fat and neuroprotection effects. However, the effect of TSG in promoting the recovery of the nerve system after TBI is not fully understood. PARP1 is a key enzyme in repair of the damage in DNA, which is activated by binding to DNA breaks, initiating both single-strand and double-strand DNA break repair. And we thought that overexpression of TSG might enhance the effect of TSG in TBI treatment. In this study, we firstly detected the oxidative stress response related molecules in serum samples of TBI patients and a TBI mice model, and found that oxidative stress response was activated after TBI, and TSG would reduce this effect. We further noticed that inflammation related molecules presented a similar trend with oxidative stress response related molecules. These results indicated that inflammatory response and oxidative stress processes were both activated after TBI, and reduced after TSG treatment. We further detected that the apoptosis related proteins and anti-oxidative proteins were increased after TSG treatment, and these effects were enlarged after overexpression of PARP1. We further noticed that these effects might be mediated by inhibition of the Ras/JNK signalling pathway. Thus, we thought overexpression of PARP1 might enhance the therapeutic effect of TSG in TBI treatment.

show abstract

“…It has been revealed that enhancing neurogenesis, angiogenesis, and immunoregulation by secreting chemokine and growth factors are involved in the functional recovery induced by stem cell/progenitor cell-based interventions. 96 –99 Several clinical trials in cell-based treatment for TBI recovery have demonstrated safety of this therapeutic approach. 100,101 However, the administration route, dose, and time window still remain controversial.…”

Section: Therapeutic Studies In Animal Models Of Tbimentioning

confidence: 99%

“…MSCs were mainly isolated from the bone marrow, umbilical cord, and adipose tissue. 99,101,102 The administration dose of MSCs ranges from 0.1 to 20 million cells per kg body weight. 96 The approaches of lateral ventricle and intravenous injection have been utilized.…”

Section: Therapeutic Studies In Animal Models Of Tbimentioning

confidence: 99%

Traumatic Brain Injury

et al. 2017

View full text Add to dashboard Cite

Traumatic brain injury (TBI) presents in various forms ranging from mild alterations of consciousness to an unrelenting comatose state and death. In the most severe form of TBI, the entirety of the brain is affected by a diffuse type of injury and swelling. Treatment modalities vary extensively based on the severity of the injury and range from daily cognitive therapy sessions to radical surgery such as bilateral decompressive craniectomies. Guidelines have been set forth regarding the optimal management of TBI, but they must be taken in context of the situation and cannot be used in every individual circumstance. In this review article, we have summarized the current status of treatment for TBI in both clinical practice and basic research. We have put forth a brief overview of the various subtypes of traumatic injuries, optimal medical management, and both the noninvasive and invasive monitoring modalities, in addition to the surgical interventions necessary in particular instances. We have overviewed the main achievements in searching for therapeutic strategies of TBI in basic science. We have also discussed the future direction for developing TBI treatment from an experimental perspective.

show abstract

The impact of bone marrow-derived mesenchymal stem cells on neovascularisation in rats with brain injury

Cited by 13 publications

References 20 publications

Efficacy of Cell-Based Therapies for Traumatic Brain Injuries

Efficacy of Cell-Based Therapies for Traumatic Brain Injuries

PARP1 might enhance the therapeutic effect of tetrahydroxystilbene glucoside in traumatic brain injury via inhibition of Ras/JNK signalling pathway

Traumatic Brain Injury

Contact Info

Product

Resources

About